All In Biotech

Drug Trial Radar · NCT01959139

S1313, PEGPH20 in Treating Patients With Newly Diagnosed Metastatic Pancreatic Cancer

S1313, A Phase IB/II Randomized Study of Modified FOLFIRINOX + Pegylated Recombinant Human Hyaluronidase (PEGPH20) Versus Modified FOLFIRINOX Alone in Patients With Good Performance Status Metastatic Pancreatic Adenocarcinoma

Last checked: Nov 19, 2026Latest source record: Feb 9, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 126 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

126

Actual

Start

Jan 23, 2014

Primary completion

Apr 2019

Study completion Nov 9, 2023

Sponsor

Lead sponsor
SWOG Cancer Research NetworkResearch network
Sponsor type
Research network
Collaborators
National Cancer Institute (NCI); Halozyme Therapeutics
First posted
Oct 9, 2013

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This partially randomized phase I/II trial studies the side effects and best dose of pegylated recombinant human hyaluronidase (PEGPH20) when given together with combination chemotherapy and to see how well they work compared with combination chemotherapy alone in treating patients with newly diagnosed pancreatic cancer that has spread to other places in the body. Pegylated recombinant human hyaluronidase may help chemotherapy drugs work better by making tumor cells more sensitive to the drugs. Drugs used in chemotherapy, such as leucovorin calcium, fluorouracil, irinotecan hydrochloride, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether combination chemotherapy is more effective with or without pegylated recombinant human hyaluronidase in treating pancreatic cancer.

Conditions

  • Metastatic Pancreatic Adenocarcinoma

Interventions

  • PEGPH20Drug

    3 ug/kg on Day 1, IV over 15 minutes

  • OxaliplatinDrug

    85 mg/m\^2, on Day 2, IV over 2 hours

  • LeucovorinDrug

    400 mg/m\^2, on Day 2, IV over 2 hours

  • IrinotecanDrug

    180 mg/m\^2, on Day 2, IV over 1.5 hours

  • 5-fluorouracilDrug

    2,400 mg/m\^2, Days 2-4, IV over 46 hours

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Phase I: Maximum Tolerated Dose (MTD) of PEGPH20 in Combination With mFOLFIRINOXTime frame: 2 cycles of 14 days
  2. Phase II: Overall SurvivalTime frame: From date of registration to date of death due to any cause, assessed up to 3 years

Locations

154 sites in 1 country. Site status is shown where the registry gives one.

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • University of Arizona Cancer Center-North Campus

    Tucson, Arizona

  • The University of Arizona Medical Center-University Campus

    Tucson, Arizona

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills - Peninsula Hospitals

    Burlingame, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • City of Hope Corona

    Corona, California

  • UC Irvine Health Cancer Center-Newport

    Costa Mesa, California

  • Sutter Davis Hospital

    Davis, California

  • City of Hope Comprehensive Cancer Center

    Duarte, California

  • Los Angeles County-USC Medical Center

    Los Angeles, California

  • USC / Norris Comprehensive Cancer Center

    Los Angeles, California

  • Fremont - Rideout Cancer Center

    Marysville, California

  • Memorial Medical Center

    Modesto, California

  • Palo Alto Medical Foundation-Camino Division

    Mountain View, California

  • Palo Alto Medical Foundation-Gynecologic Oncology

    Mountain View, California

  • Sutter Cancer Research Consortium

    Novato, California

  • UC Irvine Health/Chao Family Comprehensive Cancer Center

    Orange, California

  • Palo Alto Medical Foundation Health Care

    Palo Alto, California

  • Sutter Cancer Centers Radiation Oncology Services-Roseville

    Roseville, California

  • Sutter Roseville Medical Center

    Roseville, California

  • Sutter General Hospital

    Sacramento, California

  • University of California Davis Comprehensive Cancer Center

    Sacramento, California

  • California Pacific Medical Center-Pacific Campus

    San Francisco, California

  • Palo Alto Medical Foundation-Santa Cruz

    Santa Cruz, California

  • Sutter Pacific Medical Foundation

    Santa Rosa, California

  • Palo Alto Medical Foundation-Sunnyvale

    Sunnyvale, California

  • Gene Upshaw Memorial Tahoe Forest Cancer Center

    Truckee, California

  • Sutter Cancer Centers Radiation Oncology Services-Vacaville

    Vacaville, California

  • Sutter Solano Medical Center/Cancer Center

    Vallejo, California

  • City of Hope West Covina

    West Covina, California

  • Smilow Cancer Hospital-Derby Care Center

    Derby, Connecticut

Showing 40 of 154 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.